Skip to main content
. 2015 Feb 10;6(9):6850–6861. doi: 10.18632/oncotarget.3190

Figure 4. Kaplan–Meier estimates of the probability of survival.

Figure 4

(A) The five-year overall survival (OS) rate was 50.7% of 209 ESCC patient; (B) High TACC3 expression level was significantly correlated to OS ( p = 0.017) in all ESCC patients. Furthermore, cases were stratified by pathological stage. (C) High TACC3 expression level was significantly associated with OS (p = 0.028) in ESCC patients at Stage II; (D) No significant difference in 5-year OS rate was found between TACC3 high-expression and low-expression in ESCC patients at Stage III.